Literature DB >> 26843486

The Secreted Protein Rv1860 of Mycobacterium tuberculosis Stimulates Human Polyfunctional CD8+ T Cells.

Vijaya Satchidanandam1, Naveen Kumar2, Sunetra Biswas2, Rajiv S Jumani2, Chandni Jain2, Rajni Rani3, Bharti Aggarwal3, Jaya Singh3, Mohan Rao Kotnur4, Anand Sridharan5.   

Abstract

We previously reported that Rv1860 protein from Mycobacterium tuberculosis stimulated CD4(+)and CD8(+)T cells secreting gamma interferon (IFN-γ) in healthy purified protein derivative (PPD)-positive individuals and protected guinea pigs immunized with a DNA vaccine and a recombinant poxvirus expressing Rv1860 from a challenge with virulent M. tuberculosis We now show Rv1860-specific polyfunctional T (PFT) cell responses in the blood of healthy latently M. tuberculosis-infected individuals dominated by CD8(+) T cells, using a panel of 32 overlapping peptides spanning the length of Rv1860. Multiple subsets of CD8(+) PFT cells were significantly more numerous in healthy latently infected volunteers (HV) than in tuberculosis (TB) patients (PAT). The responses of peripheral blood mononuclear cells (PBMC) from PAT to the peptides of Rv1860 were dominated by tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10) secretions, the former coming predominantly from non-T cell sources. Notably, the pattern of the T cell response to Rv1860 was distinctly different from those of the widely studied M. tuberculosis antigens ESAT-6, CFP-10, Ag85A, and Ag85B, which elicited CD4(+) T cell-dominated responses as previously reported in other cohorts. We further identified a peptide spanning amino acids 21 to 39 of the Rv1860 protein with the potential to distinguish latent TB infection from disease due to its ability to stimulate differential cytokine signatures in HV and PAT. We suggest that a TB vaccine carrying these and other CD8(+) T-cell-stimulating antigens has the potential to prevent progression of latent M. tuberculosis infection to TB disease.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26843486      PMCID: PMC4820513          DOI: 10.1128/CVI.00554-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  66 in total

1.  Differential effects of cytolytic T cell subsets on intracellular infection.

Authors:  S Stenger; R J Mazzaccaro; K Uyemura; S Cho; P F Barnes; J P Rosat; A Sette; M B Brenner; S A Porcelli; B R Bloom; R L Modlin
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

2.  Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection.

Authors:  R J Mazzaccaro; M Gedde; E R Jensen; H M van Santen; H L Ploegh; K L Rock; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  Definition of the full extent of glycosylation of the 45-kilodalton glycoprotein of Mycobacterium tuberculosis.

Authors:  K M Dobos; K H Khoo; K M Swiderek; P J Brennan; J T Belisle
Journal:  J Bacteriol       Date:  1996-05       Impact factor: 3.490

4.  Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection.

Authors:  Nadia Caccamo; Giuliana Guggino; Simone A Joosten; Giuseppe Gelsomino; Paola Di Carlo; Lucina Titone; Domenico Galati; Marialuisa Bocchino; Alessandro Matarese; Alfredo Salerno; Alessandro Sanduzzi; Willeke P J Franken; Tom H M Ottenhoff; Francesco Dieli
Journal:  Eur J Immunol       Date:  2010-08       Impact factor: 5.532

Review 5.  Variation in protection by BCG: implications of and for heterologous immunity.

Authors:  P E Fine
Journal:  Lancet       Date:  1995-11-18       Impact factor: 79.321

6.  Analysis of a genomic DNA expression library of Mycobacterium tuberculosis using tuberculosis patient sera: evidence for modulation of host immune response.

Authors:  R R Amara; V Satchidanandam
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

7.  CTL response to Mycobacterium tuberculosis: identification of an immunogenic epitope in the 19-kDa lipoprotein.

Authors:  N Mohagheghpour; D Gammon; L M Kawamura; A van Vollenhoven; C J Benike; E G Engleman
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

8.  Cloning, sequencing, and expression of the apa gene coding for the Mycobacterium tuberculosis 45/47-kilodalton secreted antigen complex.

Authors:  A Laqueyrerie; P Militzer; F Romain; K Eiglmeier; S Cole; G Marchal
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

9.  An antimicrobial activity of cytolytic T cells mediated by granulysin.

Authors:  S Stenger; D A Hanson; R Teitelbaum; P Dewan; K R Niazi; C J Froelich; T Ganz; S Thoma-Uszynski; A Melián; C Bogdan; S A Porcelli; B R Bloom; A M Krensky; R L Modlin
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

10.  Polyfunctional T cells in human tuberculosis.

Authors:  Katalin A Wilkinson; Robert J Wilkinson
Journal:  Eur J Immunol       Date:  2010-08       Impact factor: 5.532

View more
  4 in total

1.  Computational identification and characterization of antigenic properties of Rv3899c of Mycobacterium tuberculosis and its interaction with human leukocyte antigen (HLA).

Authors:  Ritam Das; Kandasamy Eniyan; Urmi Bajpai
Journal:  Immunogenetics       Date:  2021-07-06       Impact factor: 2.846

2.  A Systematic Review on Novel Mycobacterium tuberculosis Antigens and Their Discriminatory Potential for the Diagnosis of Latent and Active Tuberculosis.

Authors:  Noëmi R Meier; Marc Jacobsen; Tom H M Ottenhoff; Nicole Ritz
Journal:  Front Immunol       Date:  2018-11-09       Impact factor: 7.561

3.  Tuberculosis patients display a high proportion of CD8+ T cells with a high cytotoxic potential.

Authors:  Leslie Chávez-Galán; Jhacqueline Illescas-Eugenio; Magaly Alvarez-Sekely; Renata Baez-Saldaña; Raúl Chávez; Ricardo Lascurain
Journal:  Microbiol Immunol       Date:  2019-07-26       Impact factor: 1.955

4.  Microarray-based selection of a serum biomarker panel that can discriminate between latent and active pulmonary TB.

Authors:  Zhihui Li; Jianjun Hu; Pengchong Liu; Dan Cui; Hongqin Di; Shucai Wu
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.